Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Jan 16th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Alibaba Health Information Technology, Xiaomi, Tencent, China Hongqiao, Gf Securities.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Jan 16th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Alibaba Health Information Technology, Xiaomi, Tencent, China Hongqiao, Gf Securities.


HK Short Interest Weekly: Alibaba Health, Xiaomi, Tencent, China Hongqiao

Overseas Chinese Equities, Aequitas Research

Ming Lu

Overseas Chinese Equities

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>State Administration for Market Regulation (SAMR) launched an investigation into TCOM.</li>
<li>TCOM has a market share above 65% in the travel market.</li>
<li>We believe SAMR will not ruin TCOM - it just warns TCOM not to kill small companies.</li>
</ul>


State Administration for Market Regulation (SAMR) launched an investigation into TCOM.
TCOM has a market share above 65% in the travel market.
We believe SAMR will not ruin TCOM - it just warns TCOM not to kill small companies.


Trip.com (TCOM, 9961.HK): No Concern for Authorities Investigation

Asian Equities Analyst, Logistics & Transport, Tracking Traffic

Daniel Hellberg

Asian Equities Analyst, Logistics & Transport

Tracking Traffic

Focusing on Asian logistics, transportation, and travel companies

<ul>
<li>Chinese authorities have confirmed an investigation into Trip.com anticompetitive practices</li>
<li>The company could face fines of 1% - 10% of 2025 net revenue (up to US$800 mn)</li>
<li>A less likely outcome could be sweeping changes to the company's business model; AVOID</li>
</ul>


Chinese authorities have confirmed an investigation into Trip.com anticompetitive practices
The company could face fines of 1% - 10% of 2025 net revenue (up to US$800 mn)
A less likely outcome could be sweeping changes to the company's business model; AVOID


Trip.com Subject of Antitrust Investigation | Potentially Faces Large Fine or Forced Change to Model

<ul>
<li>We analysed the earning revision of component stocks of HS TECH in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Kuaishou, MEITUAN, JD.COM, LI AUTO, BIDU.</li>
</ul>


We analysed the earning revision of component stocks of HS TECH in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Kuaishou, MEITUAN, JD.COM, LI AUTO, BIDU.


HS TECH Index Earning Revision (Dec): Kuaishou, MEITUAN, JD.COM, LI AUTO, BIDU, Bidu, Meituan

<ul>
<li>We analysed the earning revision of component stocks of HSI in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on MEITUAN, CCB, China Life, HENGAN INTERNATIONAL, LI AUTO, ICBC, XIAOMI.</li>
</ul>


We analysed the earning revision of component stocks of HSI in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on MEITUAN, CCB, China Life, HENGAN INTERNATIONAL, LI AUTO, ICBC, XIAOMI.


HSI Index Earning Revision (Dec): MEITUAN, CCB, China Life, HENGAN INTERNATIONAL, LI AUTO, ICBC

Singapore

Trip.com Group is a leading global one-stop travel platform offering accommodation reservations, transportation ticketing, packaged tours, and corporate travel management services. It operates a portfolio of brands including Trip.com, Ctrip, Skyscanner, and Qunar. The company was founded in June 1999 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Trip.com Group (9961 HK)

HK Short Interest Weekly: Alibaba Health, Xiaomi, Tencent, China Hongqiao

We analyzed the latest HK SFC report for aggregate short position as of Jan 16th and highlight short interest changes in Alibaba Health (241 HK),...

Ke Yan, CFA, FRM

Trip.com (TCOM, 9961.HK): No Concern for Authorities Investigation

SAMR launched an investigation into TCOM. TCOM has a market share above 65% in the travel market. We believe SAMR will not weaken TCOM, but just...

Ming Lu

Trip.com Subject of Antitrust Investigation | Potentially Faces Large Fine or Forced Change to Model

News of an antitrust investigation into Trip.com sent its shares plummeting last week. The company could face fines, changes to existing practices,...

Tracking Traffic

HS TECH Index Earning Revision (Dec): Kuaishou, MEITUAN, JD.COM, LI AUTO, BIDU, Bidu, Meituan

We analyzed HS TECH's consensus for Dec 2025 and highlighted changes of EPS in Kuaishou, MEITUAN, JD.COM, LI AUTO, BIDU.

Ke Yan, CFA, FRM

HSI Index Earning Revision (Dec): MEITUAN, CCB, China Life, HENGAN INTERNATIONAL, LI AUTO, ICBC

We analyzed HSI's consensus for Dec 2025 and highlighted changes of EPS in MEITUAN (3690 HK), CCB (939 HK), China Life (2628 HK), HENGAN...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)